Free cash flow remains persistently negative, with a $32.3 million deficit in 2026Q1 exacerbated by $14.2 million in stock-based compensation that obscures the true magnitude of cash burn.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Cash from Operations | -36.26M | -42.48M | -44.81M | -89.72M | -70.04M | -152.55M | -81.44M | -76.48M | -70.27M | -65.19M | -92.53M | -71.84M | 13.4M | 1.81M | 21.98M |
| Operating CF Margin % | - | -10.43% | -13.43% | -72.09% | -134.29% | -1510.85% | -1075.62% | -1448.29% | -2695.59% | -155.21% | -385.14% | -299.01% | 42.36% | 6.26% | 406.28% |
| Operating CF Growth % | 71.95% | 5.19% | 50.06% | -28.09% | 54.08% | -87.33% | -6.47% | -8.84% | -7.8% | 29.55% | -28.81% | -636.24% | 639.76% | -91.76% | - |
| Net Income | -58.06M | -61.6M | -39.14M | -66.07M | -67.21M | -158.16M | -94.31M | -94.94M | -91.3M | -64.34M | -112.39M | -29.62M | -3.21M | -6.56M | -9.79M |
| Depreciation & Amortization | 3.37M | 3.06M | 2.06M | 1.29M | 1.14M | 1.44M | 1.82M | 2.5M | 2.68M | 2.64M | 1.29M | 829K | 302K | 592K | 675K |
| Stock-Based Compensation | 38.59M | 48.96M | 37.38M | 13.53M | 10.75M | 12.04M | 10.58M | 9.94M | 9.23M | 9.59M | 5.32M | 2.63M | 1.69M | 352K | 473K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -190K | 315K | -262K | -1.02M | 11K | -86K | 65K | 0 | 0 | 0 |
| Other Non-Cash Items | 8.06M | -1.55M | 4.05M | 4.91M | 4.84M | 4.25M | 3.37M | 3.3M | 792K | 567K | 540K | 458K | 1.59M | 3.51M | 950K |
| Working Capital Changes | -28.23M | -31.35M | -49.17M | -43.39M | -19.57M | -11.92M | -3.21M | 2.98M | 9.35M | -13.66M | 12.79M | -46.2M | 13.02M | 3.92M | 29.67M |
| Change in Receivables | -36.37M | -14.14M | -35.67M | -14.3M | -7.23M | -502K | 750K | 85K | 10.71M | -10.8M | 0 | 2.58M | 3.85M | -3.36M | -3.07M |
| Change in Inventory | -22.15M | -31.92M | -41.7M | -21.14M | -28.35M | -10.37M | -750K | -3.41M | 1.88M | -1.9M | 0 | -2.08M | 743K | -730K | -578K |
| Change in Payables | 14.47M | 3.23M | 4.86M | 279K | 6.58M | -1.35M | 3.44M | 39K | -2.73M | -1.03M | 2.15M | -371K | 831K | 1.14M | -105K |
| Cash from Investing | -21.8M | -8.96M | -18.32M | -131.25M | 18.41M | 50.95M | -31.44M | 23.37M | -29.89M | 65.29M | -131.08M | -3.45M | -1.86M | -278K | -128K |
| Capital Expenditures | -1.24M | -1.49M | -1.01M | -344K | -55K | -1.87M | -324K | -325K | -311K | -2.35M | -4.87M | -3.45M | -1.86M | -278K | -128K |
| CapEx % of Revenue | 0.29% | 0.37% | 0.3% | 0.28% | 0.11% | 18.49% | 4.28% | 6.15% | 11.93% | 5.61% | 20.25% | 14.38% | 5.87% | 0.96% | 2.37% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -52.81M | 31.44M | -23.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 1.8M | 52.81M | -31.44M | 23.7M | -29.58M | 67.64M | -126.21M | 0 | 0 | 0 | 0 |
| Cash from Financing | 58.47M | 54.51M | 106.59M | 146.29M | 75.34M | 83M | 22.78M | 155.48M | 103.55M | 685K | 191.2M | 75.01M | 61.31M | -1K | 270K |
| Debt Issued (Net) | 48.67M | 48.67M | 99.45M | 22.39M | -6.07M | -19.44M | -125K | 0 | 49.29M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 9.8M | 5.84M | 8.14M | 119.24M | 71.63M | 101.15M | 21.05M | 154.9M | 53.77M | 0 | 190.57M | 74.32M | 61.24M | -1K | -20K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2K | -2K | -20K |
| Other Financing | 0 | 0 | -1M | 4.67M | 9.78M | 1.3M | 1.85M | 574K | 491K | 685K | 631K | 689K | 69K | 0 | 290K |
| Net Change in Cash | 401K | 3.07M | 43.46M | -74.67M | 23.71M | -18.6M | -90.1M | 102.36M | 3.38M | 785K | -32.41M | -282K | 72.85M | 1.53M | 22.12M |
| Free Cash Flow | -37.5M | -43.98M | -45.82M | -90.06M | -70.1M | -154.42M | -81.76M | -76.81M | -70.58M | -67.55M | -97.4M | -75.29M | 11.54M | 1.53M | 21.85M |
| FCF Margin % | -8.77% | -10.8% | -13.73% | -72.36% | -134.4% | -1529.35% | -1079.9% | -1454.44% | -2707.52% | -160.82% | -405.39% | -313.39% | 36.5% | 5.3% | 403.92% |
| FCF Growth % | 23.05% | 4.03% | 49.12% | -28.48% | 54.6% | -88.87% | -6.44% | -8.82% | -4.5% | 30.65% | -29.36% | -752.4% | 652.84% | -92.98% | - |
| FCF per Share | -0.15 | -0.18 | -0.19 | -0.41 | -0.44 | -1.48 | -0.91 | -1.19 | -1.26 | -1.42 | -2.43 | -3.29 | 0.62 | 0.11 | 1.64 |
| FCF Conversion (FCF/Net Income) | 0.65x | 0.69x | 1.14x | 1.36x | 1.04x | 0.96x | 0.86x | 0.81x | 0.77x | 1.01x | 0.82x | 2.43x | -4.17x | -0.28x | -2.25x |
| Interest Paid | 8.4M | 0 | 11.41M | 4.24M | 2.9M | 3.47M | 4.2M | 4.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 489K | 0 | 266K | 51K | 6K | 4K | 1K | 2K | 4K | 3K | 0 | 69K | 0 | 160K | 0 |
Regulatory reimbursement uncertainty
As reported in financial statements, Ardelyx's operating cash flow frequently diverges from net income, with OCF/NI ratios fluctuating wildly from 2.11 in 2024Q4 to -51.48 in 2025Q4, indicating that accounting accruals and non-cash adjustments significantly obscure the underlying cash-generating capacity of the core commercial business.
The extreme variance in the OCF/NI ratio suggests that reported net income is heavily influenced by non-operating items or timing differences in revenue recognition rather than consistent cash inflows. Investors should monitor whether this disconnect persists as the company attempts to scale its commercial footprint, as the current lack of alignment between earnings and cash flow complicates the assessment of true operational viability.
Based on recent SEC filings, Ardelyx's free cash flow trajectory is characterized by persistent deficits, with a cash burn of $32.3 million in 2026Q1 alone, highlighting the company's ongoing struggle to achieve self-sustaining operations despite the commercial launch of its primary therapeutic assets.
The inability to maintain positive free cash flow suggests that the current revenue ramp is insufficient to cover the high fixed costs associated with the company's specialized sales force. This trajectory implies that the business remains in a capital-intensive growth phase where cash outflows are likely to continue until market penetration reaches a critical threshold.
According to quarterly data, working capital changes have been a significant source of volatility, ranging from a $18.9 million outflow in 2025Q2 to a $7.7 million inflow in 2025Q4, which suggests that inventory management and collection cycles are not yet optimized for stable cash flow generation.
These erratic swings in working capital indicate potential inefficiencies in managing channel inventory or delays in receiving payments from wholesalers and partners. Such instability warrants further investigation, as it may mask underlying challenges in the company's ability to convert product sales into actual cash on a predictable basis.
Data from recent financial disclosures reveals that stock-based compensation has consistently reached double-digit millions per quarter, peaking at $14.2 million in 2026Q1, which effectively obscures the true magnitude of the company's cash burn by inflating the operating cash flow figures through non-cash accounting adjustments.
While stock-based compensation is a standard tool for talent retention in biotechnology, its scale relative to the company's negative operating cash flow suggests that the actual economic cost of operations is higher than the headline cash flow metrics imply. Investors should consider the dilutive impact of this compensation strategy alongside the persistent cash deficits when evaluating the company's long-term funding requirements.
Quick answers to the most common questions about buying ARDX stock.
Ardelyx, Inc. (ARDX) generated $-42.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Ardelyx, Inc. (ARDX) reported negative free cash flow of $44.0M in 2025, indicating capital requirements exceeded cash from operations.
Ardelyx, Inc. (ARDX) spent $1.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.